Phase 1 Renal Cell Carcinoma trials recruiting now

All Renal Cell Carcinoma trials, every phase

Other phases for Renal Cell Carcinoma

Phase 1 Renal Cell Carcinoma trials

• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
  NCT07623369 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 9 locations
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of VET3-TGI in Patients With Solid Tumors
  NCT06444815 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
  NCT06682793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
  NCT07115043 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
  NCT03093688 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
  NCT07297667 · Phase: Phase 1 · Ages: 15 Years and older · Sex: All (male and female) · 2 locations
• GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
  NCT06265025 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• IDOV-Immune for Advanced Solid Tumors
  NCT06910657 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
  NCT04787042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
  NCT05024214 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• Retifanlimab and Ruxolitinib In Solid Malignancies
  NCT07219576 · Phase: Phase 1, Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
  NCT06582017 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
  NCT06966024 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.